“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017 World Medical Imaging Congress. The poster data, showing high sensitivity and the selective ability of tumor-targeting MagSense nanoparticles to discriminate between HER2-overexpressing and non-overexpressing cancer cells in mice, contribute to the evidence Imagion Biosystems is building in support of the company’s plan for first-in-human clinical trials.
Download the poster “Specific detection of HER-2 positive tumors in mice using superparamagnetic relaxometry (SPMR).”
Successful Placement of A$3M
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The